Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of 177Lu-3BP-227 in NTSR1-expressing advanced solid tumors
NL-OMON50308Phase 2Completed
- Sponsor
- Ipsen
- Start
- May 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zalsenertant tetraxetan lutetium Lu-177 in pancreatic adenocarcinoma (PDAC), colorectal cancer (CRC), gastric cancer (GC) and 4 more, sponsored by Ipsen. Primary endpoints: Maximum tolerated cumulative activity or maximum administered cumulative activity and Objective response rate. Started May 2020; status: completed.
02
Drugs
zalsenertant tetraxetan lutetium Lu-177
03
Conditions
pancreatic adenocarcinoma (PDAC)colorectal cancer (CRC)gastric cancer (GC)gastrointestinal stromal tumor (GIST)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON50308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50308.